167. マルファン症候群 Marfan syndrome Clinical trials / Disease details
臨床試験数 : 20 / 薬物数 : 39 - (DrugBank : 10) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 50
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01949233 (ClinicalTrials.gov) | October 2013 | 6/8/2013 | The Oxford Marfan Trial | A Randomised, Double-blind, Placebo-controlled Pilot Trial of Irbesartan, Doxycycline and a Combination on Markers of Vascular Dysfunction in the Marfan Syndrome, Using Cardiovascular Magnetic Resonance Imaging | Marfan Syndrome | Drug: Irbesartan 150-300mg capsules daily for 6 months;Drug: Doxycycline 100-200mg capsules daily for 6 months;Drug: Doxycycline placebo capsules daily for 6 months;Drug: Irbesartan placebo capsules daily for 6 months | University of Oxford | Oxford University Hospitals NHS Trust | Recruiting | 13 Years | N/A | Both | 56 | Phase 2 | United Kingdom |
| 2 | EUCTR2010-023612-14-GB (EUCTR) | 08/03/2013 | 20/12/2012 | The Oxford Marfan Trial | A randomised, double-blind, placebo-controlled pilot trial of irbesartan, doxycycline and a combination on markers of vascular dysfunction in the Marfan syndrome, using cardiovascular magnetic resonance imaging - The Oxford Marfan Trial Version 1.0 | Marfan syndrome. MedDRA version: 14.1;Level: PT;Classification code 10026829;Term: Marfan's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Aprovel Product Name: Aprovel INN or Proposed INN: Irbesartan Trade Name: Vibrox 100mg Capsules Product Name: Vibrox INN or Proposed INN: Doxycycline Hyclate Ph.Eur | Clinical Trials and Research Governance | NULL | Not Recruiting | Female: yes Male: yes | 56 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United Kingdom | ||
| 3 | EUCTR2010-019302-16-GB (EUCTR) | 13/09/2010 | 17/08/2010 | A prospective, randomised, placebo-controlled, double blind, multi-centre study of the effects of Irbesartan on aortic dilatation in Marfan syndrome | A prospective, randomised, placebo-controlled, double blind, multi-centre study of the effects of Irbesartan on aortic dilatation in Marfan syndrome - The AIMS Study | Marfan Syndrome | Trade Name: Aprovel Product Name: Aprovel INN or Proposed INN: Irbesartan INN or Proposed INN: Irbesartan INN or Proposed INN: Irbesartan | Royal Brompton and Harefield NHS Foundation Trust | NULL | Not Recruiting | Female: yes Male: yes | 490 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | United Kingdom |